本文選題：食管癌　切入點(diǎn)：干細(xì)胞　出處：《北京協(xié)和醫(yī)學(xué)院》2017年博士論文　論文類型：學(xué)位論文

【摘要】：目前,食管癌占全世界范圍內(nèi)癌癥死亡率的第六位,在我國(guó)位于癌癥死亡率的第四位。食管癌在全世界不同地區(qū)和人種間的發(fā)病率有著很大的不同,因此環(huán)境因素與遺傳因素均與食管癌的發(fā)病相關(guān)。食管癌主要包括食管鱗狀細(xì)胞癌和食管腺癌兩大病理類型,其中食管鱗狀細(xì)胞癌約占食管惡性腫瘤的90%,我國(guó)中部地區(qū)及中亞是食管鱗癌的主要流行地區(qū)。在我國(guó)食管癌病因?qū)W研究領(lǐng)域,上世紀(jì)七八十年代通過對(duì)河南省林州市食管癌高發(fā)現(xiàn)場(chǎng)深入的病因?qū)W研究明確了亞硝胺類物質(zhì)、霉變食物、微量元素缺乏等是我國(guó)食管癌的重要化學(xué)病因。這其中,在林縣食管癌高發(fā)現(xiàn)場(chǎng)分離得到的甲基芐基亞硝胺是目前已知最強(qiáng)的誘導(dǎo)大鼠食管癌的化學(xué)致癌物,并且其誘導(dǎo)的大鼠食管癌病理形態(tài)與人食管鱗狀細(xì)胞癌的發(fā)生時(shí)序相平行,因此,甲基芐基亞硝胺主要被用來構(gòu)建大鼠食管癌動(dòng)物模型。該動(dòng)物模型對(duì)研究食管癌的發(fā)生、發(fā)展機(jī)制及化學(xué)預(yù)防有著重要意義。對(duì)于上皮來源實(shí)體瘤的研究如實(shí)體瘤內(nèi)部不同細(xì)胞體外克隆形成能力的差異,使得人們對(duì)腫瘤異質(zhì)性有了更深入的認(rèn)識(shí)。腫瘤干細(xì)胞理論的提出為解釋腫瘤細(xì)胞的異質(zhì)性提供了一定的理論依據(jù)。目前,食管鱗癌干細(xì)胞標(biāo)志物的研究仍處于探索階段,特異程度較高的標(biāo)志物依然有待進(jìn)一步尋找。二甲雙胍是目前應(yīng)用最廣泛的2型糖尿病治療藥物,近期一些流行病學(xué)研究顯示二甲雙胍可以降低多種實(shí)體瘤的發(fā)生,這其中二甲雙胍降低食管癌發(fā)生的流行病學(xué)研究也偶有報(bào)道,但二甲雙胍降低食管癌發(fā)生發(fā)展的分子機(jī)制卻未見明確報(bào)道。本研究中,我們首先構(gòu)建了兩種NMBzA給藥途徑誘導(dǎo)的大鼠食管癌動(dòng)物模型并優(yōu)化動(dòng)物模型,得到了從增生、不典型增生到癌階段的動(dòng)態(tài)病理標(biāo)本。免疫組化染色分析了目前被證實(shí)的大鼠食管干細(xì)胞標(biāo)志物及人食管鱗癌干細(xì)胞標(biāo)志物等在大鼠食管癌發(fā)生發(fā)展過程中的動(dòng)態(tài)變化情況。其次,我們利用NMBzA皮下給藥模型進(jìn)行了二甲雙胍預(yù)防食管鱗癌發(fā)生的動(dòng)物模型研究,證實(shí)了二甲雙狐能夠有效抑制NMBzA誘導(dǎo)的大鼠食管癌及其癌前病變的發(fā)生與發(fā)展,并揭示了 AMPK/mTOR信號(hào)轉(zhuǎn)導(dǎo)通路是二甲雙胍抑制食管癌發(fā)生的主要作用靶點(diǎn)。最后,通過體外細(xì)胞實(shí)驗(yàn)進(jìn)一步證實(shí)二甲雙胍可以抑制食管上皮永生化細(xì)胞與食管癌細(xì)胞的增殖能力,使上述細(xì)胞的細(xì)胞周期阻滯在G0/G1期,并促進(jìn)細(xì)胞凋亡的發(fā)生,上述現(xiàn)象與二甲雙胍抑制食管癌細(xì)胞Bcl-2及cyclinD1的表達(dá)相關(guān)。此外,食管癌細(xì)胞的遷移運(yùn)動(dòng)能力與平板克隆形成能力及成球性生長(zhǎng)能力也顯著受到抑制,這與二甲雙胍影響食管癌細(xì)胞中AMPK/mTOR、PI3K/Akt及Stat3信號(hào)轉(zhuǎn)導(dǎo)通路和降低干性相關(guān)基因表達(dá)相關(guān)。綜上所述,我們的研究成功構(gòu)建了 NMBzA誘導(dǎo)的大鼠食管癌動(dòng)物模型,為大鼠食管癌發(fā)生發(fā)展過程中各重要基因的突變與表達(dá)量的改變以及研究食管鱗癌干細(xì)胞的起源問題提供了標(biāo)本來源。通過體內(nèi)、體外實(shí)驗(yàn)證實(shí)了二甲雙胍預(yù)防食管癌發(fā)生發(fā)展的分子機(jī)制,為二甲雙胍在臨床中預(yù)防及治療食管癌癌前病變提供一定的理論基礎(chǔ)。
[Abstract]:At present, esophageal cancer accounted for worldwide cancer mortality in China in sixth, cancer mortality fourth. The incidence of esophageal cancer in the world in different regions and races are very different, so the incidence of environmental and genetic factors were associated with esophageal cancer esophageal cancer mainly includes two. Pathological types of esophageal squamous cell carcinoma and adenocarcinoma of the esophagus, and esophageal squamous cell carcinoma accounts for about 90% of malignant tumor of esophagus, the central region of China and Central Asia is the major epidemic areas of esophageal cancer. In the field of study on etiology of esophageal cancer in China, the last century in 70s and 80s by the Linzhou city of Henan Province, a high incidence of esophageal cancer etiology research field further clear the nitrosamines, moldy food, lack of trace elements are important chemical etiology of esophageal cancer in China. Among these, the separated methyl in Lin County, a high risk area of esophageal cancer Benzyl nitrosamine induced esophageal cancer in rats is currently the strongest known chemical carcinogens, and the timing of rats induced by esophageal cancer and pathological morphology of human esophageal squamous cell carcinoma are parallel, therefore, METHYLBENZYLNITROSAMINE mainly is used to construct esophageal carcinoma animal model rats. The animal model study on esophageal cancer, has important significance and development mechanism of chemoprevention. For solid tumors of epithelial origin such as differences in tumor cells in vitro in different colony forming ability, which make people have a deeper understanding of tumor heterogeneity. The cell theory provides a theoretical basis for the interpretation of tumor heterogeneity the tumor stem cells. At present, esophageal squamous cell carcinoma stem cell marker research is still in the exploratory stage, the higher degree of specific markers remains to be further search. Metformin is the most Type 2 diabetes wide drug treatment, some recent epidemiological studies suggest that metformin may reduce the occurrence of a variety of solid tumors, which metformin reduces epidemiological study on esophageal cancer have also been reported, but the molecular mechanism of metformin reduces the development of esophageal cancer has not been clearly reported. In this study, and optimize the animal model of esophageal cancer in rats the animal model we first constructed two NMBzA administration induced, obtained from hyperplasia, dysplasia and carcinoma specimens dynamic pathological stage. Immunohistochemical staining analysis confirmed the rat esophageal stem cell markers and human esophageal squamous cell carcinoma stem cell markers have dynamic changes in the development process in esophageal carcinoma rats. Secondly, we use the NMBzA model by subcutaneous administration of metformin on animal model of esophageal carcinoma, syndrome The two armor double fox to the occurrence and development of esophageal carcinoma rats effectively inhibit NMBzA induced and precancerous lesions, and reveals the AMPK/mTOR signal transduction pathway is the main effect of metformin inhibited esophageal cancer target. Finally, through in vitro experiments further confirmed that two metformin can inhibit the proliferation ability of human immortalized esophageal epithelial cells with esophageal cancer cells, block the cell cycle of the cells in the G0/G1 phase, and promotes cell apoptosis, the expression of the above phenomenon with metformin inhibits Bcl-2 and cyclinD1 esophageal cancer cells. In addition, esophageal cancer cell migration and colony forming ability and Ballability growth ability also significantly inhibited. The effects of metformin and AMPK/mTOR in esophageal carcinoma cells, PI3K/Akt and Stat3 signal transduction pathway and reduce the stemness related genes expression. In summary, I Our study successfully constructed the animal model of NMBzA induced rat esophageal cancer, esophageal cancer rat mutated each important gene during the development and expression and the origin of esophageal squamous cell carcinoma stem cells provide a source of specimen. In vivo, in vitro experiments confirmed the molecular mechanism of the occurrence and development of esophageal and metformin for the prevention of cancer, and provide a theoretical basis for the treatment of esophageal precancerous lesions of metformin in clinic.

【學(xué)位授予單位】：北京協(xié)和醫(yī)學(xué)院
【學(xué)位級(jí)別】：博士
【學(xué)位授予年份】：2017
【分類號(hào)】：R735.1

【相似文獻(xiàn)】

相關(guān)期刊論文 前10條

1 邵成偉,王培軍,田建明,張火俊,王敏杰,曾浩;直接注射法制作大鼠肝癌模型[J];中國(guó)醫(yī)學(xué)影像技術(shù);2002年08期

2 邵成偉,王培軍,田建明,張火俊,左長(zhǎng)京,郝西彥,王敏杰,陳煒;大鼠種植型肝癌外周血TNF-α表達(dá)水平的變化[J];中國(guó)臨床醫(yī)學(xué)影像雜志;2003年04期

3 趙玖,趙清正,張春燕,侯充,王萍,于樹玉;大鼠肝癌組織中α_2-巨球蛋白等幾種分泌型蛋白基因表達(dá)的變化(簡(jiǎn)報(bào))[J];中國(guó)醫(yī)學(xué)科學(xué)院學(xué)報(bào);1992年05期

4 趙麗軍，印木泉，徐冠雄，方君成，曠雙遠(yuǎn)，勵(lì)雁峰;酚類化合物抑制大鼠肝癌啟動(dòng)機(jī)理的研究[J];衛(wèi)生毒理學(xué)雜志;1995年01期

5 宋衛(wèi)生,毛華,徐明符;中華麥飯石對(duì)肝癌大鼠免疫功能的作用[J];免疫學(xué)雜志;1997年03期

6 白咸勇,賈秀紅,成令忠,顧云娣,鐘翠平,朱繼紅;干擾素和卡介苗對(duì)大鼠肝癌發(fā)生的影響[J];解剖科學(xué)進(jìn)展;1997年03期

7 王錦波,何振平;移植法建立大鼠肝癌模型[J];實(shí)驗(yàn)動(dòng)物科學(xué)與管理;1999年02期

8 王昌俊,劉友章,許鑫梅,李建軍,張茂林,鄧力;中藥960合劑抗大鼠肝癌作用的研究[J];中醫(yī)藥學(xué)刊;2004年08期

9 趙衛(wèi)東,管生,彭衛(wèi)軍,周康榮,唐峰,毛建,曹光;新型1.5T MR對(duì)大鼠誘發(fā)肝癌進(jìn)行~1H-MRS掃描可行性的初步分析[J];中國(guó)癌癥雜志;2004年04期

10 施公勝,郝傳錚,黃丹,顧美珍;聯(lián)合中藥治法抑制大鼠肝癌的實(shí)驗(yàn)研究[J];河南腫瘤學(xué)雜志;2005年04期

相關(guān)會(huì)議論文 前10條

1 王偉;許戈良;莢衛(wèi)東;馬金良;李建生;葛勇勝;余繼海;;雷帕霉素抑制大鼠肝癌的生長(zhǎng)及轉(zhuǎn)移[A];第十二屆全國(guó)肝癌學(xué)術(shù)會(huì)議論文匯編[C];2009年

2 胡娟;胡宗海;王超;冷言冰;蔡亞青;李林;;大鼠肝癌促進(jìn)模型的建立和相關(guān)基因HCC-X mRNA表達(dá)譜差異分析[A];第十屆全軍檢驗(yàn)醫(yī)學(xué)學(xué)術(shù)會(huì)議論文匯編[C];2005年

3 歐超;曹驥;楊春;李瑗;唐艷萍;李黃羿;蘇建家;黃天壬;;金花茶抑制黃曲霉毒素B1誘發(fā)大鼠肝癌過程中的化學(xué)預(yù)防作用及其機(jī)制[A];全國(guó)腫瘤流行病學(xué)和腫瘤病因?qū)W學(xué)術(shù)會(huì)議論文集[C];2011年

4 T3建中;丁延yD;;偶氮染料姌v|肝癌及注射甲r老偎卮笫蟮母臥策鴠a，

本文編號(hào)：1605250